1. Professional Expericance
Glaxo SmithKline Inc.
RTP, North Carolina
April 2001- Present Scientific Director
Respiratory Medicine Development
North American Medical Affairs
Role requires a strong scientific and commercial understanding of the respiratory
market as well as the ability to effectively communicate scientific information and
develop clinical programs that support registration and promotion of respiratory
medicine. Support US and global strategy for clinical development programs and
regulatory submissions of new and marketed respiratory medicines.
Develop phase II,-IV clinical studies. Extensive experience in areas of asthma
disease progression, asthma management, HPA axis function, and device testing
and specifications. Lead USMA Asset Scientist for FF/BREO. Member of
FF/BREO asthma MMT and Launch strategy Teams. Member of the US Medical
Affairs launch team for Flovent and Advair launches. Experienced in processing
clinical and economic data for regulatory submission, publication, and formulary
acceptance. Clinical lead for pediatric exclusivity for Ventolin and MDI dose
counter programs. Prepare clinical sections of FDA briefing documents, Pediatric
Study Plans (PSP) and EU Pediatric Investigation Plans (PIP). Medical Affairs
scientist on Bioequivalence/Generic project team. Write, edit or review
manuscripts, product monographs, sales training materials and promotional sales
aids. Train sales staff and Regional Medical Scientists on key scientific
data. Member of MMT, adult and pediatric asthma strategy teams, Clinical Lead
for Study Conduct Teams and UMAP/program development working groups.
Possess strong communication skills, ability to work across functional groups,
knowledge of drug development and commercial as well as a good
understanding of the competitive landscape.
April 94 – April2001 Glaxo Wellcome, Inc.
RTP, North Carolina
Clinical Program Head
Principal Clinical Research Scientist
Respiratory Medical Affairs
Project and program level management of phase IV clinical drug studies. Develop novel approaches
to support product launch and promotional activities. Manage Contract Research
Organizations conducting large multi-center clinical drug trials. Review and
interpret clinical data and write/edit study reports, manuscripts, and abstracts.
Forecast clinical budgets and manpower needs. Review and edit sales detail aids
and physician teaching materials.
Aug. 87 - April 94 Bristol-Myers Squibb Inc.
Wallingford, Connecticut
Senior Clinical Scientist - Infectious Diseases Clinical Scientist - Infectious
Diseases
Project management, clinical plan administration, protocol development, NDA support and review.
Budget and resource negotiations. Supervise clinical trial monitored and

2. oversee Contract Research Organizations. Worked with 2nd and 3rd generation cephalosporins and
anti-virals for claims in adults and children. Area of expertise includes upper and
Oct. 83 - Aug. 87 Bristol-Myers Squibb Inc.
Pharmaceutical Research Institute
Wallingford, Connecticut
Research Scientist
Pre-clinical characterization of novel Antibiotic compounds. Evaluate data in support of the IND.
Supervised one technician.
Jan 82 - June 83 University of New York at Buffalo Medical School
Buffalo, New York
Research Technician - Infectious Diseases
Research in the areas of antibiotic resistance, peptidoglycan structure and anaerobic bacterial
growth.
June 81 - Dec. 81 University of New York College at Buffalo
Buffalo, New York
Graduate Assistant
Department of Biology
Research in the area of host-parasite interactions
Education
Degree: Bachelor of Science in Biology May 1981.
Salisbury University, Salisbury, MD 21801
Graduate School, 1981- 1983, State University of New York,
College at Buffalo, Buffalo, NY
Related Courses
PhRMA Asthma Course
PhRMA Clinical Study Management Course
Effective Presentations
Influence Management, Glaxo Wellcome 5-day management Core
Technical Writing
Management Leadership
The Successful Negotiator
Matrix Management
Project Management
Organizations/ Honors
Beta Beta Beta National Biology Society,
Omicron Delta Kappa National Honor Society
Campus Life and Leadership Award- Salisbury University

3. Publications
Manuscripts
Fung-Tomc, J.; Lincourt W.; Thater C.; Kessler, R.; “Comparison of the Inhibitory and
Bactericidal Activity of Aztreonam and Amikacin against Gram-Negative Aerobic
Bacilli.” Annals of Clinical and Laboratory Science, Vol. 18, No. 6: 463-467, 1988.
Raphael, G., Lanier, R.,Baker, J., Edwards, L., Rickard, K., Lincourt, W. “A Comparison Of
Multiple Doses Of Fluticasone propionate and Beclomethasone dipropionate in subjects with
persistent asthma” Journal of Allergy and Clinical Immunology., May 1999
Sorkness, C,. LaForce, C,. Storms, W,. Lincourt, W,. Edwards, L,. Rogenes, P,..“ The Effects of
the Inhaled Corticosteroids Fluticasone propionate, Triamcinolone acetonide, and Flunisolide
and oral Prednisone on the HPA-axis in Adult Asthmatics,”...Clinical Therapeutics, March 1999
Berger, W., Ford, L,. Mahr, T,. Nathan, R,. Crim, C,. Edwards, Lisa,. Wightman, D,. Lincourt,
W,. Rickard, R,. “Efficacy and Safety of Fluticasone propionate 250mcg administered once daily
in patients with persistent asthma treated with or without inhlaed corticosteroids.” Annals of
Allergy, Asthma and Immunology Vol.89 Number 4, October 2002, pg. 393-399.
Keton Sheth, MD; Jonathan A. Bernstein, MD; William R. Lincourt, BS; Kunal K. Merchant,
PhD; Lisa D. Edwards, PhD; Courtney C. Crim, MD; Paul M. Dorinsky, MD, “Patient
Perceptions of an Inhaled Asthma Medication administered as an Inhalation Powder via the
DISKUS®™
or as an Inhalation Aerosol via a Metered Dose inhaler” Annals of Allergy, Asthma,
& Immunology. 2003;91:55– 60.
Jacqueline R. Carranza Rosenzweig, Lisa Edwards, William Lincourt, Paul Dorinsky and
Richard L ZuWallack, “THE EFFECT OF LUNG FUNCTION AND DAILY SYMPTOMS ON
ASTHMA QUALITY OF LIFE IN PATIENTS WITH PERSISTENT ASTHMA” Respiratory
Medicine (2004) 98, 1157–1165
Courtney Crim, MD; Mark Holmes; Benjamin Lee, PharmD; Robb Cavanaugh; William
Lincourt.,Evaluation of Particle Size Distribution of Ventolin HFA Administered via Metered
Dose Inhaler With and Without Valved Holding Chambers, Annals of Allergy, Asthma, &
Immunology. 94(1):80-85, January 2005.
Nancy K. Ostrom, MD, Bruce A. Decotiis, MD, William R. Lincourt, BS, Lisa D. Edwards,
Ph.D, Kathleen M. Hanson, BS, Jacqueline R. Carranza Rosenzweig, Pharm.D., Courtney Crim,
MD, Comparative Efficacy and Safety of Low-Dose Fluticasone propionate and Montelukast in
Children with Persistent Asthma, . Journal of Pediatrics August 2005.
Richard L. Wasserman, MD; Ketan Sheth, MD; William R. Lincourt, BS; Nicholas W.
Locantore, PhD; Jacqueline Carranza Rosenzweig, Pharm.D; Courtney Crim, MD Real World
Assessment of a Metered Dose Inhaler with Integrated Dose Counter. Allergy & Asthma
Proceedings 27:486 –492, 2006;
.

4. E.M. KERWIN, M.D., M.M. TARPAY, M.D., K. KIM, M.D., M. J. NOONAN, M.D., W.
LINCOURT, B.S., R. TRIVEDI, M.S., A. ELLSWORTH, B.S., A. DAVIS-ALLEN, M.D.
Safety and Efficacy of a New Albuterol Hydrofluoroalkane Formulation for Treating Asthma
Symptoms in Children 2 to Less than 4 Years of Age Pediatric Asthma, Allergy, and
Immunology. Volume 19, Number 2, 2006. pp 81-90.
K. SHETH, R. L. WASSERMAN, W. R. LINCOURT, N. W. LOCANTORE, J . CARRANZA-
ROSENZWEIG, C. CRIM; Fluticasone propionate/salmeterol hydrofluoroalkane via metered-
dose inhaler with integrated dose counter: performance and patient satisfaction Ltd Int J Clin
Pract, October 2006, 60, 10, 1218–1224
James A. Hedrick, James W. Baker, Arthur B. Atlas, Aftab A. Naz, William R. Lincourt, Roopa
Trivedi, Anna Ellworth and Angela M. Davis; Safety of Daily Albuterol in Infants with a History
of Bronchospasm: A Multi-Center Placebo; Controlled Trial, The Open Respiratory Medicine
Journal, 2009, 3, 100-106
Mintz M., Gilsenan A.W., Bui C.L., Ziemiecki R., Stanford R.H., Lincourt W., Ortega
H;. Predictors of Asthma Control: Results from the Asthma Control Characteristics and
Prevalence Survey Study (ACCESS) Current Medical Research and Opinion 2009 25:10 (2523-
2531)
William Lincourt, Richard H Stanford, Alicia Gilsenan, Dana DiBenedetti and Hector Ortega;
Assessing Primary Care Physician’s Beliefs and Attitudes of Asthma Exacerbation Treatment
and Follow-up. The Open Respiratory Medicine Journal, 2010, 4, 9-15 9
Kaashmiri M., Shepard J., Goodman B., Lincourt W.R., Trivedi R., Ellsworth A., Davis A.M.
Safety of daily albuterol in infants with a history of bronchospasm: A multi-center placebo
controlled trial; Pediatric Emergency Care 2010 26:3 (197-202)
Liu A.H., Gilsenan A.W., Stanford R.H., Lincourt W., Ziemiecki R., Ortega H. Status of asthma
control in pediatric primary care: Results from the pediatric asthma control characteristics and
prevalence survey study (ACCESS) Journal of Pediatrics 2010 157:2 (276-281.e3)
Stanford R.H., Gilsenan A.W., Ziemiecki R., Zhou X., Lincourt W.R., Ortega H; Predictors of
uncontrolled asthma in adult and pediatric patients: Analysis of the asthma control characteristics
and prevalence survey studies (ACCESS). Journal of Asthma 2010 47:3 (257-262)
Katial R.K., Bernstein D., Prazma C.M., Lincourt W.R., Stempel D.A. Long-term treatment with
fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone
propionate alone. Allergy and Asthma Proceedings 2011 32:2 (127-136)
Other Publications
Murphy, T.; Lincourt, W.; “Studies on Mutants of Clostridium perfringens.” State University of
New York Department of Medicine Research Conference, 1983.

5. Fung-Tomc, J.; Lincourt, W.; Thater, C.; Kolek, B.; Huczkoe, E. Denbleyker, K.; and Kessler,
R.; “In Vitro Activity of a New Fluoronapthyridone BMY 40062.” International Conference of
Antimicrobial Agents and Chemotherapy, 1988.
Jaurequi, L.; Lincourt W.; Doyle, C.; Tenney, J.; and Multi-Center Study Group. “Comparisons
of Cefepime (FEP) and Ceftazidime (CAZ) for Treatment of Bacteremia and Sepsis - A
Physiologic Analysis of Efficacy.” International Conference of Antimicrobial Agents and
Chemotherapy, 1993.
McCabe, R.; Farkas, S.; Lincourt W.’ Doyle, C.; and the Cefepime Multi-Center Study
Group. “Efficacy Summary of International Experience with Cefepime (FEP) vs. Ceftazidime
(CAZ) or Cefotaxime (CTX) for Pneumonia.” International Conference of Antimicrobial Agents
and Chemotherapy, 1993.
Galant, S.P.; Lincourt, W.; Rogenes, P.; Field, E. A.; Wisniewski, M. “Fluticasone Propionate
Aqueous Nasal Spray versus Antihistamines for Sneezing and Nasal Itching.” American College
of Allergists and Immunologists, 1994.
Kapke, G.; Lincourt, W., “Immunochemical Versus HPLC Measurement of Serum Cortisol
During A 6 Hour Cortrosyn Infusion In Steroid Naive Asthmatics” International Conference of
the American Thoracic Society, May 1996.
LaForce, C., Goldstein, M., Storms, W., Levy, B., Li, J., Littlejohn, T., McCluskey, D., Lincourt,
W., Rogenes, P., Schaberg, A., Wisniewski, M., “Comparision of Inhaled Fluticasone
Propionate And Flunisolide Effects on The HPA Axis As Assessed By The 6-Hour Cosyntropin
Infusion Testing”. The European Resp. Journal, Vol 9, Supplement 23, Sept 1996.
Sorkness, C., Howland, W., Stricker, W., Tita, J., Noveck, R., Dockhorn, R., Talbot, S.,
Lincourt, W., Rogenes, P., Schaberg, A., Wisniewski, M., “Comparision of Inhaled Fluticasone
Propionate And Triamcinolone Acetonide Effects on The HPA Axis As Assessed By The 6-Hour
Cosyntropin Infusion Testing”. The European Resp. Journal, Vol 9, Supplement 23, Sept 1996.
Stroms, W., Howland WC., Sorkness CA., LaForce C., Goldstein , M., Lincourt, WR., Rogenes
PR., Schaberg, AE., Edwards, L., “ Fluticasone Propionate, Triamcinolone Acetonide and
Flunisolide have similar Effects on the HPA Axis. American Academy of Allergy Asthma and
Immunology, March 1997.
GD Raphael, JW Baker, P Chervinsky, J Grossman, MF Goldstein, , PR Rogenes, L Edwards,
WR Lincourt, “Low Dose Fluticasone Propionate(FP) Is More Effective Than Higher Doses of
Beclomethasone Dipropionate (BDP) In Patients With Mild To Moderate Asthma” American
Academy of Allergy Asthma and Immunology, March 1998
JJ Murray, B Friedman, P Chervinsky, C Fogarty, JW Baker , PR Rogenes, L Edwards,.WR
Lincourt,”Asthma Severity as a Determinant for Selecting Appropriate Doses of Fluticasone
Propionate(FP) or Beclomethasone Dipropionate(BDP)” American Academy of Allergy Asthma
and Immunology, March 1998

6. JJ Murray, B Friedman, P Chervinsky, C Fogarty, JW Baker , PR Rogenes, L Edwards, WR
Lincourt, “Fluticasone Propionate(FP) Is More Effective Than Higher Doses of Beclomethasone
Dipropionate (BDP) In Patients With Moderate Asthma” International Conference of the
American Thoracic Society, May 1998
Srebro SH, Rogenes PR, Edwards L, Lincourt WR: Comparison of efficacy and HPA effects of
fluticasone propionate versus flunisolide in patients with mild to moderate asthma ;, Am J Respir
Crit Care Med 1998; 157 (3): A406
C Crim, WR Lincourt, AL Stevens, TP Shah, LD Edwards, SM Harding, KA Rickard; Once-
Daily Low Dose Fluticasone Propionate Diskus as Initial therapy in the Treatment of Adult
Subjects with Persistent Asthma - A Subset Analysis of the Clinical Efficacy of Once-Daily
dosing in Subjects with Mild-to-Moderate Asthma., American Academy of Allergy Asthma and
Immunology, March 2000
Lisa D Edwards, Ken M Kral, James R Johnson, William R. Lincourt, A RETROSPECTIVE
DESCRIPTIVE MEDICAL CLAIMS ANALYSIS OF INCREASED MEDICAL RISK IN
ASTHMA MANAGEMENT FOR PATIENTS PRESCRIBED MONTELUKAST COMPARED
TO FLUTICASONE PROPIONATE, American Academy of Allergy Asthma and Immunology,
March 2001
Chervinsky P, Kalberg C, Goode-Sellers S, Edwards L, Lincourt W, Rickard K. A Comparison
of
Low Dose Fluticasone Propionate and Montelukast in Patients Stratified Based on Baseline
Asthma Severity. Amer J Resp Crit Care Med; 163(5):A428, April 2001.
Berger WE, Mahr TA, Crim C, Wightman DS, Edwards LD, Lincourt, WR, Rickard KA;
Flovent 250mcg Administered Once Daily is Effective Initial Therapy in Patients with Persistent
Asthma Currently Treated with Bronchodilators Alone, ACAAI in November 2001
Ford L, Crim C, Lincourt WR, Wightman D, Edwards LD, Rickard KA. Once Daily Low Dose
Fluticasone Propionate In The Treatment Of Adult And Adolescent Subjects With Persistent
Asthma Currently Using Low Doses Of Inhaled Corticosteroids. (AAAAI March 2002).
K. K. Sheth, W. R. Lincourt, L. D. Edwards, P. Dorinsky, C. Crim; Patient Perceptions of an
Inhaled Asthma Medication Administered as an Inhalation Powder via the Diskus or as an
Aerosol via a Metered Dose Inhaler (AAAAI March 03)
J.R.Carranza Rosenzweig, Pharm.D, M.S., L.D. Edwards, Ph.D , W.R .Lincourt, B.S. , R.H.
Stanford, Pharm.D. and P.M. Jhingran, Ph.D. CORRELATION BETWEEN SYMPTOMS,
LUNG FUNCTION AND QUALITY OF LIFE
IN PATIENTS WITH PERSISTENT ASTHMA, (International Conference of the American
Thoracic Society May 2003)

7. N.K.Ostrom, MD , B.A.DeCotiis, MD , W.R.Lincourt, BS , L.D.Edwards, PhD and C. Crim,
MD ; A Comparison of Low Dose Fluticasone Propionate and Montelukast in Children 6-12
Years of Age with Persistent Asthma. (International Conference of the American Thoracic
Society May 2003)
Courtney Crim, MD; Benjamin Lee, PharmD; William Lincourt; Mark Holmes, BSc (Hons );
and Robb Cavanaugh. GlaxoSmithKline, Inc., Research Triangle Park, NC, USA, IN-VITRO
COMPARISON OF THE PERFORMANCE OF VALVED HOLDING CHAMBERS (VHC)
FOR DELIVERY OF VENTOLIN®
HFA INHALATION AEROSOL, (International Conference
of the American Thoracic Society, May 2003)
Carranza Rosenzweig, J; Lincourt, W ; Edwards, L ; Rickard, K; Cost-efficacy of Fluticasone
Propionate Compared To Montelukast in the Treatment of Pediatric Asthma, (ACAAI 2003)
W. R. Lincourt, C. Crim, K. M. Hanson, L. D. Edwards; Fluticasone Propionate (FP) was
Superior to Montelukast (MON) in Producing at Least a 2-Step Improvement in Asthma Severity
in Children 6-12 Years of Age. AAAAI, March 2004 (POSTER #348)
C. Crim, M.D. , R. Trivedi , B. Lee , W. Wu, T. Weeks and W. Lincourt; Asthma Exacerbations
Associated with Upper Respiratory Tract Infections in Asthmatic Children Under 4 years of Age
Treated with Fluticasone Propionate . Poster Presentation at a Thematic Poster Session A53
Asthma Therapy (International Conference of the American Thoracic Society, May 2004)
Courtney Crim, William Lincourt, Roopa Trivedi, Anna Ellsworth, Angela Davis-Allen,Ventolin
HFA MDI, safety in children 24-<48 months old with asthma-like symptoms AAAAI, March
2005 Poster presentation.
K.K. Sheth, MD, MBA , W.R. Lincourt, BS , B.T. Lee, Pharm. D2
, N.W. Locantore, Ph. D and
C. Crim, MD; A Study to Evaluate the Handling Performance of Fluticasone
Propionate/Salmeterol HFA MDI with Counter in Subjects with Asthma or COPD; American
Thoracic Society, May 2005 poster presentation.
Crim, Lincourt, Locantore, Rosenzweig, Handling Performance and Patient Satisfaction of a
Metered Dose Inhaler(MDI) With Integrated Dose Counter in Patients With COPD. ACCP Chest
meeting. ACCP – Poster- Montreal, Quebec, Canada Oct. 29-Nov. 3, 2005
Sheth K, Crim C, Carranza Rosenzweig J, Lincourt W, Locantore. Reliability and Patient
Satisfaction with MDI with Dose Counter.Lincourt W, Poster- ACAAI - Anaheim, CA Nov. 5-
7, 2005
Sheth K, Lincourt W, Crim C, , Locantore W, Carranza Rosenzweig J. Patient Satisfaction with
Fluticasone Propionate/Salmeterol (FSA) HFA with an Integrated Dose Counter. Poster- ERS -
Copenhagen, Denmark Sept.17-21, 2005
Angela Davis, William Lincourt, Roopa Trivedi, et.al. Safety of Ventolin HFA MDI in Children
Birth-<24 Months Old with Symptoms of Bronchospasm Presented at the Annual Meeting of
American Academy of Allergy, Asthma and Immunology March 3-7, 2006 Miami Beach, FL

8. Julie Shepard MD* Courtney Crim MD Roopa Trivedi MS William Lincourt BS Anna Ellsworth
BS Angela Davis MD Ohio Pediatrics Inc., Huber Heights, OH RESULTS OF A
RANDOMIZED CONTROLLED TRIAL ON REPEAT ALBUTEROL DOSING IN ACUTELY
WHEEZING CHILDREN <24 MONTHS OLD, Pediatric presented at CHEST: Chest Medicine
Wednesday, October 24, 2007
J. Hedrick, M.D., A.M. Davis, M.D., W. Lincourt, B.S., R. Trivedi, M.S., A.Ellsworth, B.S., C.
Crim, M.D Cardiac Safety Of Ventolin HFA In Children <48 Months Old.. AAAAI Jan. 2007:
 Hedrick
A.M. Davis, M.D., W. Lincourt, B.S., R. Trivedi, M.S., A. Ellsworth, B.S., C. Crim,
M.D.Ventolin HFA: Safety In Children <48 Months Old Prepared abstract (Mar. 2007) NMA
meeting
A.M. Davis, M.D., W. Lincourt, B.S., R.Trivedi, M.S., A. Ellsworth, B.S., C.Crim, M.D
Efficacy of Ventolin® HFA MDI Cumulative Dosing in Children <24 Months Old.. AAAAI
Jan.2007
Shepard M.D., C Crim, M.D., R Trivedi, M.S., W Lincourt, B.S., A Ellsworth, B.S., AM Davis,
M.D.Results of a randomized controlled trial on repeat albuterol dosing in acutely wheezing
children <24 months old. J ACCP 2007 (May 2007)
C.Crim, M.D., R.Trivedi, M.S., W. Lincourt, B.S., A. Ellsworth, B.S., A.M. Davis,
M.D. Ventolin HFA MDI efficacy in children <24 months old in the acute care setting. abstract
(Mar. 2007) NMA 2007
J. Hedrick, M.D., A.M. Davis, M.D., W. Lincourt, B.S., R. Trivedi, M.S., A.Ellsworth, B.S., C.
Crim, M.D.Cardiac Safety Of Ventolin HFA In Children <48 Months Old. (Jan. 2007)
AAAAI 2007
Hector Ortega, M.D., W. Lincourt, B.S., Amanda Emmett, Safety and Efficacy of Fluticasone
propionate (FP) plus Salmeterol via a Single Device compared with Fluticasone propionate
Alone in Patients Greater than or Equal to 50 Years of Age
MS. American College of Chest Physicians: Chicago IL, October 20-25, 2007
J.P. Mitchell, PhD, H. MacKay, HBSc, M.W. Nagel, HBSc, K.J. Wiersema, BA, A.L. Cripps,
PhD, S.M. Pischel, BSc and W.R. Lincourt, BS; In-vitro Performance of HFA Fluticasone
Propionate (FP) in Two Valved Holding Chambers (Spacers) Tested with Facemasks Attached at
Low Inspiratory Flow Rates and Extended Delay Times . American Academy of Allergy,
Asthma & Immunology; March 14-18, 2008; Philadelphia,
H. Ortega1
, D. Stempel1
, L. Sutton1
, W. Lincourt1
, L. Frith2
, R. Forth2
, W. Busse; on behalf of the
GOAL Steering Committee3
; 1
GlaxoSmithKline, RTP, NC, 2
GlaxoSmithKline, Stockley Park,
UNITED KINGDOM, 3
University of Wisconsin School of Medicine, Madison, WI. Comparative
Safety and Efficacy of Fluticasone Propionate plus Salmeterol via Diskus® Versus Fluticasone

9. Propionate in Subjects with Asthma Greater than or Equal to 55 and 65 Years of Age. AAAAI,
2008
Jolyon P. Mitchell1, Heather Mackay, Mark W. Nagel, Kimberly J. Wiersema, Alan L. Cripps,
Sylvine M. Pischel2 and William R. Lincourt, IN-VITRO PERFORMANCE OF HFA
FLUTICASONE PROPIONATE (FP) IN TWO VALVED HOLDING CHAMBERS
(SPACERS) TESTED WITH FACEMASKS ATTACHED AT LOW INSPIRATORY FLOW
RATES AND EXTENDED DELAY TIMES. ATS International Conference
May 16 – 21, 2008, Toronto, Ontario
Jolyon Mitchell, Mark Nagel, Kimberly Wiersema, Heather Mackay, Alan Cripps, Sylvine
Pischel and William Lincourt, IN VITRO PERFORMANCE OF TWO VALVED HOLDING
CHAMBERS (SPACERS) FOR PAEDIATRIC USE TESTED WITH FACEMASKS
ATTACHED IS UNAFFECTED BY ROUTINE USE AND CLEANING. ERS, Annual
Congress October 4 – 8, 2008, Berlin, Germany.
HG Ortega AW Gilsenan, W Lincourt, RM Ziemiecki, C Lankevich, RH Stanford
The Effect of Body Mass Index on Asthma Control: Results from the Asthma Control
Characteristics and Prevalence Survey Study (ACCESS) AAAAI 2009 poster presentation
RH Stanford, AW Gilsenan, W Lincourt, C Lankevich, RM Ziemiecki, DA Stempel, HG Ortega
Predictors of Asthma Control: Results from the Asthma Control Characteristics and Prevalence
Survey Study (ACCESS) AAAAI 2009 presentation.
R H Stanford, PharmD, MS, A W Gilsenan, PhD, W Lincourt, MS, C Lankevich, MS, A
Vanderpuije, MS2
and H G Ortega, MD, ScD1
Predictors of Asthma Control in Pediatric
Asthmatics: Results from the Pediatric Asthma Control Characteristics and Prevalence Survey
Study (ACCESS) ATS 2009.
Kelly, H.W.; Lincourt, W; Kral, K.; Stempel;THE RELATIONSHIP BETWEEN FEF25-75 and
FEV1 FOLLOWING TREATMENT WITH FLUTICASONE PROPIONATE OR FLUTICASONE
PROPIONATE/SALMETEROL VIA DISKUS®2010 Annual Meeting of the American College of Allergy,
Asthma and Immunology (ACAAI)